Susana R Kerkhof-Garde
University of Amsterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Susana R Kerkhof-Garde.
The Journal of Infectious Diseases | 1998
Oscar Pontesilli; Michèl R. Klein; Susana R Kerkhof-Garde; Nadine G. Pakker; Frank de Wolf; Hanneke Schuitemaker; Frank Miedema
To establish correlates of protective immunity during human immunodeficiency virus type 1 (HIV-1) infection, the frequencies of circulating cytotoxic T lymphocyte (CTL) precursors (p) directed against 4 HIV-1 gene products (reverse transcriptase, gag, nef, and env) were evaluated in HIV-1-infected homosexual men who progressed to AIDS and in long-term survivors over time. For both groups, HIV-1-specific CTL responses had similar kinetics and magnitude. At maximum expansion, HIV-1-specific CTLp had a median frequency of 0.2% mononuclear cells in both progressors and long-term survivors, with peaks of 0.5% and 2%, respectively. Long-term survivors maintained the established CTLp pool and presented a persistently predominant gag-specific response. The fraction and, to a lesser extent, the frequency of gag-specific CTLp were inversely correlated with virus load. In progressors, general T cell function and measurable HIV-1-specific CTLp frequencies dropped simultaneously, suggesting a further loss of virus control due to the ensuing immunodeficiency.
AIDS Research and Human Retroviruses | 1999
Oscar Pontesilli; Patrizia Carotenuto; Susana R Kerkhof-Garde; Roos Mt; Ireneus P. M. Keet; Roel A. Coutinho; Jaap Goudsmit; Frank Miedema
To establish immunologic correlates of progression to AIDS in long-term survivors of HIV-1 infection, HIV-1-specific T cell-mediated responses, together with T cell reactivity to recall antigens, were studied in frozen samples collected after 5 and 8 years of documented HIV-1 infection. Eight of 21 homosexual men, who remained asymptomatic and maintained CD4+ T cell numbers >400 cells/microl for 9 years of HIV-1 infection, progressed to AIDS (CDC 1993 definition) within 12.5 years of infection (late progressors, LPs). The remainders showed minimal deterioration of immune parameters (long-term nonprogressors, LTNPs). CD4+ T cell numbers and T cell function measured at years 5 and 8 of follow-up were comparable in the two groups. At both time points responses to recall antigens did not significantly differ between the two groups, although a significant decline of lymphoproliferative responses to Candida and tetanus toxoid was observed in LPs. Circulating HIV-1-specific cytotoxic T lymphocyte precursors were found in broad frequency ranges in both LPs and LTNPs and, similarly, no significant differences were found in comparing the breadth of serum neutralizing activity against heterologous HIV-1 primary isolates. In contrast, lymphoproliferative responses to p24gag, but not p17gag or gp160env, were detected only in LTNPs and were totally absent in LPs at both time points (p < 0.01). Our data suggest that the presence of circulating p24-specific CD4+ T cells may reflect effective viral control and be predictive of subsequent favorable clinical course in long-term asymptomatic individuals.
Immunology Letters | 1999
Oscar Pontesilli; Susana R Kerkhof-Garde; Nadine G. Pakker; Daan W. Notermans; Marijke Th. L. Roos; M. R. Klein; Sven A. Danner; Frank Miedema
To evaluate functional T-cell recovery during combination therapy with ritonavir, lamivudine (3TC), and zidovudine (ZDV), peripheral blood mononuclear cells (PBMC) were obtained from 4 HIV-1 infected patients (baseline values: 40 403 CD4+ T-cells/microl; 4.6-6.4 log HIV-1 RNA copies/ml) before HAART administration (week -1) and after 5, 20, and 37 weeks of treatment on average. In vitro lymphoproliferative responses (LPR) to C. albicans, tetanus toxoid, and M. tuberculosis protein purified derivative (PPD), as recall antigens (Ag), and to recombinant HIV-1 Gag-p24 and p17 were measured by 3H-Thymidine incorporation. LPR to recall Ag, almost undetectable before therapy, appeared in all four patients during HAART soon after maximal load reduction was achieved. LPR to Gag-p17, but not to p24, became also detectable in three patients, even though remaining weak. In conclusion, improved T-lymphocyte function during HAART was achieved probably mostly as a result of lower virus inhibitory factors and cytokines.
Immunology Letters | 1997
Oscar Pontesilli; M. R. Klein; Susana R Kerkhof-Garde; Nadine G. Pakker; Frank de Wolf; Hanneke Schuitemaker; Frank Miedema
INTRODUCTION Kinetics of human immunodeficiency virus type 1 (HIV-1) cytotoxic T lymphocyte (CTL) responses and viral load were evaluated in HIV-1 infected homosexual men who progressed to AIDS within 3-6 years after seroconversion and in long-term survivors who remained AIDS-free for > 9 years with normal CD4+ T cell counts. METHODS CTL against four major HIV-1 gene products (i.e. Gag, reverse transcriptase (RT), Nef and Env) were expanded in vitro under limiting dilution conditions using antigen specific stimulation. CTL activity was measured in standard split-well 51Cr-release assay. Viral load was measured both as serum HIV-1 RNA levels and frequency of circulating CD4+ T cells productively infected with HIV-1. Polyclonal T cell function in vitro was determined in whole blood lymphocyte cultures, measuring lymphoproliferative responses to CD3 monoclonal antibody. RESULTS Long-term survival was associated with either persistently high or stable low HIV-1 specific CTL responses, accompanied by preserved in vitro polyclonal T cell reactivity and low viral load. In progressors, HIV-1 specific CTL responses were initially generated with similar kinetics as compared to long-term survivors. However, with progression to AIDS antiviral CTL activity and T cell function deteriorated simultaneously, while viral load increased. CONCLUSIONS Our results are consistent with the hypothesis that HIV-1 specific CTL are beneficial through control of viremia to the virologic set-point and contribute to maintenance of the asymptomatic phase. However, loss of HIV-1 specific immune control as part of a more general loss of T cell function is the precipitating event in AIDS pathogenesis.
Journal of Experimental Medicine | 1997
Dörte Hamann; Paul A. Baars; M.H.G. Rep; Berend Hooibrink; Susana R Kerkhof-Garde; M. R. Klein; René A. W. van Lier
Archive | 1997
Dörte Hamann; Paul A. Baars; M.H.G. Rep; Berend Hooibrink; Susana R Kerkhof-Garde; Michel R. Klein
Journal of The American Society of Nephrology | 1999
Oscar Pontesilli; Susana R Kerkhof-Garde; Daan W. Notermans; Norbert A. Foudraine; Marijke Th. L. Roos; Michèl R. Klein; Sven A. Danner; Joep M. A. Lange; Frank Miedema
Human Genetics | 1998
Oscar Pontesilli; Michèl R. Klein; Susana R Kerkhof-Garde; Nadine G. Pakker; Frank de Wolf; Hanneke Schuitemaker; Frank Miedema
Immunology Letters | 1997
Oscar Pontesilli; M. R. Klein; Susana R Kerkhof-Garde; Nadine G. Pakker; F. de Wolf; Hanneke Schuitemaker; Frank Miedema
British Journal of Haematology | 1997
Dörte Hamann; Paul A. Baars; M.H.G. Rep; Berend Hooibrink; Susana R Kerkhof-Garde; Michèl R. Klein; Lier van R. A. W